Duncan Williams Asset Management LLC Has $958,000 Position in Prothena Co. plc (NASDAQ:PRTA)

Duncan Williams Asset Management LLC lifted its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 41.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 69,199 shares of the biotechnology company's stock after acquiring an additional 20,450 shares during the period. Duncan Williams Asset Management LLC owned approximately 0.13% of Prothena worth $958,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in shares of Prothena by 14.8% during the third quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company's stock valued at $69,911,000 after acquiring an additional 539,359 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Prothena by 1,122.9% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company's stock worth $8,812,000 after purchasing an additional 483,673 shares in the last quarter. Systematic Financial Management LP lifted its holdings in Prothena by 25.8% during the 2nd quarter. Systematic Financial Management LP now owns 193,763 shares of the biotechnology company's stock valued at $3,999,000 after purchasing an additional 39,771 shares during the last quarter. Pinnacle Associates Ltd. boosted its position in Prothena by 2.3% in the third quarter. Pinnacle Associates Ltd. now owns 125,747 shares of the biotechnology company's stock valued at $2,104,000 after buying an additional 2,847 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in Prothena by 8.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,492 shares of the biotechnology company's stock worth $2,049,000 after buying an additional 9,666 shares during the last quarter. 97.08% of the stock is currently owned by institutional investors and hedge funds.

Prothena Trading Up 0.9 %

Shares of PRTA traded up $0.14 during trading hours on Friday, hitting $15.62. 340,226 shares of the stock traded hands, compared to its average volume of 419,339. The business has a fifty day moving average of $14.31 and a 200-day moving average of $17.95. Prothena Co. plc has a 1-year low of $11.70 and a 1-year high of $33.84.

Prothena (NASDAQ:PRTA - Get Free Report) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.22 million. During the same period in the prior year, the company posted $0.38 EPS. The company's revenue was down 98.9% compared to the same quarter last year. As a group, research analysts predict that Prothena Co. plc will post -2.24 earnings per share for the current year.

Wall Street Analyst Weigh In

PRTA has been the subject of a number of research analyst reports. Chardan Capital began coverage on shares of Prothena in a research note on Friday, December 20th. They issued a "buy" rating and a $40.00 target price for the company. Bank of America cut their price objective on Prothena from $26.00 to $22.00 and set a "neutral" rating for the company in a research report on Thursday, December 19th. HC Wainwright restated a "buy" rating and set a $48.00 target price (down previously from $84.00) on shares of Prothena in a report on Friday, December 20th. StockNews.com cut Prothena from a "hold" rating to a "sell" rating in a report on Tuesday, November 19th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Prothena in a report on Monday, September 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Prothena presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.50.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.